nevirapine has been researched along with Dermatitis Medicamentosa in 48 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation." | 7.72 | Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003) |
| "To draw attention to the many cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) related to nevirapine detected in a multinational case-control study of SJS and TEN." | 7.71 | Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. ( Bouwes-Bavinck, JN; Fagot, JP; Mockenhaupt, M; Naldi, L; Roujeau, JC; Viboud, C, 2001) |
| "Nevirapine treatment was stopped and was substituted with efavirenz: the patient continued on therapy with tenofovir and lamivudine." | 5.38 | Hyperhidrosis related to nevirapine therapy. ( Belda, A; Borrás-Blasco, J; Casterá, E; Jiménez, I; López-Montes, L; Rosique-Robles, D, 2012) |
| "Extended nevirapine and cotrimoxazole prophylaxis through 6 months of age among HIV-exposed uninfected infants did not appear to increase the immediate or long-term risk of neutropenia, anemia or skin-rash." | 5.16 | Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. ( Aizire, J; Bolton, SG; Brown, ER; Coovadia, H; Fowler, MG; Kamateeka, M; Musoke, PM; Shetty, AK; Stranix-Chibanda, L; Wang, J, 2012) |
| " We found that nevirapine use and pregnancy are independently associated with severe skin reaction." | 3.83 | Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. ( Boulle, A; Cohen, K; de Waal, R; Lehloenya, R; Maartens, G; Stewart, A, 2016) |
| " We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation." | 3.72 | Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003) |
| " In one case, a 43-year-old female health-care worker required liver transplantation after developing fulminant hepatitis and end-stage hepatic failure while taking NVP, zidovudine, and lamivudine as PEP following a needlestick injury (1)." | 3.71 | Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. ( , 2001) |
| "To draw attention to the many cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) related to nevirapine detected in a multinational case-control study of SJS and TEN." | 3.71 | Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. ( Bouwes-Bavinck, JN; Fagot, JP; Mockenhaupt, M; Naldi, L; Roujeau, JC; Viboud, C, 2001) |
| "Etravirine is an NNRTI option for treatment-experienced paediatric patients." | 2.79 | Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. ( Cahn, P; Chokephaibulkit, K; Dincq, S; Fourie, J; Kakuda, TN; Karatzios, C; Nijs, S; Opsomer, M; Tambuyzer, L; Tomaka, FL; Tudor-Williams, G, 2014) |
| " All papers, abstracts, or presentations, regardless of study design, that made reference to the response of patients who were switched from one NNRTI to another as a result of an adverse drug reaction were included." | 2.44 | Is it safe to switch between efavirenz and nevirapine in the event of toxicity? ( Maartens, G; Mehta, U, 2007) |
| "The mechanism of drug-induced skin rash is not well understood." | 1.91 | Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash. ( Bairam, A; Cao, Y; Liu, MC; Uetrecht, J, 2023) |
| "Nevirapine (39." | 1.43 | Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China. ( Bai, JS; Chen, JH; He, LP; Jin, YM; Kuang, YQ; Li, YY; Liu, J; Wen, J; Yu, M, 2016) |
| "Nevirapine treatment was stopped and was substituted with efavirenz: the patient continued on therapy with tenofovir and lamivudine." | 1.38 | Hyperhidrosis related to nevirapine therapy. ( Belda, A; Borrás-Blasco, J; Casterá, E; Jiménez, I; López-Montes, L; Rosique-Robles, D, 2012) |
| "We compared adverse events among breast-feeding neonates born to Kenyan mothers receiving triple-antiretroviral therapy, including either nevirapine or nelfinavir." | 1.38 | Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. ( Akoth, B; Angira, F; Masaba, R; Mills, LA; Minniear, TD; Ndivo, R; Oyaro, B; Peters, PJ; Polle, N; Thomas, TK; Zeh, C, 2012) |
| "Nevirapine-based ART was initiated in 820 women and baseline ALT or AST results were abnormal (≥ grade 1) in 113 (14%) women." | 1.36 | Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya. ( Bolu, O; Borkowf, CB; Brooks, JT; Intalapaporn, P; Kiarie, J; McConnell, MS; Mutsotso, W; Peters, PJ; Potter, D; Ratanasuwan, W; Stringer, J; Weidle, PJ; Zulu, I, 2010) |
| "Nevirapine treatment can cause a skin rash." | 1.35 | A study of the specificity of lymphocytes in nevirapine-induced skin rash. ( Chen, X; Gou, H; Mannargudi, B; Tharmanathan, T; Uetrecht, JP, 2009) |
| "All nevirapine side effects were developed in less than seven weeks." | 1.34 | Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. ( Carraro, EA; Cornelsen, TC; Dias, JM; Kondo, W; Macedo, RL; Perini, J; Prandel, E; Sasaki, Md; Sbalquiero, R, 2007) |
| "Although the skin rash was less evident on rechallenge, microscopically, the cellular infiltrate was more prominent, especially surrounding the hair follicles." | 1.32 | Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. ( Abu-Asab, MS; Shenton, JM; Teranishi, M; Uetrecht, JP; Yager, JA, 2003) |
| "Nevirapine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) that has the most common treatment limiting side effect of rash." | 1.31 | Sex differences in nevirapine rash. ( Aberg, JA; Bersoff-Matcha, SJ; Hamrick, HJ; Miller, WC; Mundy, LM; Powderly, WG; van Der Horst, C, 2001) |
| " All other patients have been taking nevirapine for more than 3 months without any adverse reaction." | 1.31 | Long-term safety and efficacy of nevirapine tolerance induction. ( Bousquet, J; Demoly, P; Fabre, J; Messaad, D; Reynes, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.25) | 18.2507 |
| 2000's | 29 (60.42) | 29.6817 |
| 2010's | 15 (31.25) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y | 1 |
| Bairam, A | 1 |
| Liu, MC | 1 |
| Uetrecht, J | 1 |
| Mohamed Saleem, TS | 1 |
| Jyothi, K | 1 |
| Babu, SC | 1 |
| Britto, GR | 1 |
| Augustine, M | 1 |
| Bayonne Kombo, ES | 1 |
| Gathse, A | 1 |
| Cohan, D | 1 |
| Mwesigwa, J | 1 |
| Natureeba, P | 1 |
| Aliba Luwedde, F | 1 |
| Ades, V | 1 |
| Plenty, A | 1 |
| Kakuru, A | 1 |
| Achan, J | 1 |
| Clark, T | 1 |
| Osterbauer, B | 1 |
| Kamya, M | 1 |
| Havlir, D | 1 |
| Tudor-Williams, G | 1 |
| Cahn, P | 1 |
| Chokephaibulkit, K | 1 |
| Fourie, J | 1 |
| Karatzios, C | 1 |
| Dincq, S | 1 |
| Opsomer, M | 1 |
| Kakuda, TN | 1 |
| Nijs, S | 1 |
| Tambuyzer, L | 1 |
| Tomaka, FL | 1 |
| Mushiroda, T | 2 |
| Borroni, RG | 1 |
| Stewart, A | 1 |
| Lehloenya, R | 1 |
| Boulle, A | 1 |
| de Waal, R | 1 |
| Maartens, G | 2 |
| Cohen, K | 1 |
| Li, YY | 1 |
| Jin, YM | 1 |
| He, LP | 1 |
| Bai, JS | 1 |
| Liu, J | 1 |
| Yu, M | 1 |
| Chen, JH | 1 |
| Wen, J | 1 |
| Kuang, YQ | 1 |
| Minzi, OM | 1 |
| Irunde, H | 1 |
| Moshiro, C | 1 |
| Colafigli, M | 1 |
| Di Giambenedetto, S | 1 |
| Bracciale, L | 1 |
| Fanti, I | 1 |
| Prosperi, M | 1 |
| Cauda, R | 1 |
| De Luca, A | 1 |
| Chen, X | 1 |
| Tharmanathan, T | 1 |
| Mannargudi, B | 1 |
| Gou, H | 1 |
| Uetrecht, JP | 3 |
| Peters, PJ | 2 |
| Stringer, J | 1 |
| McConnell, MS | 1 |
| Kiarie, J | 1 |
| Ratanasuwan, W | 1 |
| Intalapaporn, P | 1 |
| Potter, D | 1 |
| Mutsotso, W | 1 |
| Zulu, I | 1 |
| Borkowf, CB | 1 |
| Bolu, O | 1 |
| Brooks, JT | 1 |
| Weidle, PJ | 2 |
| Chantarangsu, S | 1 |
| Mahasirimongkol, S | 1 |
| Kiertiburanakul, S | 1 |
| Sungkanuparph, S | 1 |
| Manosuthi, W | 1 |
| Tantisiriwat, W | 1 |
| Charoenyingwattana, A | 1 |
| Sura, T | 1 |
| Takahashi, A | 1 |
| Kubo, M | 1 |
| Kamatani, N | 1 |
| Chantratita, W | 1 |
| Nakamura, Y | 1 |
| Wongkitisophon, P | 1 |
| Chanprapaph, K | 1 |
| Rattanakaemakorn, P | 1 |
| Vachiramon, V | 1 |
| Aizire, J | 1 |
| Fowler, MG | 1 |
| Wang, J | 1 |
| Shetty, AK | 1 |
| Stranix-Chibanda, L | 1 |
| Kamateeka, M | 1 |
| Brown, ER | 1 |
| Bolton, SG | 1 |
| Musoke, PM | 1 |
| Coovadia, H | 1 |
| Belda, A | 1 |
| Borrás-Blasco, J | 1 |
| Rosique-Robles, D | 1 |
| Jiménez, I | 1 |
| López-Montes, L | 1 |
| Casterá, E | 1 |
| Minniear, TD | 1 |
| Zeh, C | 1 |
| Polle, N | 1 |
| Masaba, R | 1 |
| Oyaro, B | 1 |
| Akoth, B | 1 |
| Ndivo, R | 1 |
| Angira, F | 1 |
| Mills, LA | 1 |
| Thomas, TK | 1 |
| Knudtson, E | 1 |
| Para, M | 1 |
| Boswell, H | 1 |
| Fan-Havard, P | 1 |
| Sullivan, JR | 1 |
| Rachlis, A | 1 |
| Phillips, E | 1 |
| Meldrum, J | 1 |
| Lackmann, GM | 1 |
| Schmidt, B | 1 |
| Niehues, T | 1 |
| Shenton, JM | 2 |
| Teranishi, M | 1 |
| Abu-Asab, MS | 1 |
| Yager, JA | 1 |
| Liechty, CA | 1 |
| Solberg, P | 1 |
| Mwima, G | 1 |
| Were, W | 1 |
| Mermin, J | 1 |
| Popovic, M | 1 |
| Chen, J | 1 |
| Masson, MJ | 1 |
| Pitche, P | 1 |
| Drobacheff-Thiebaut, C | 1 |
| Gavignet, B | 1 |
| Mercier, M | 1 |
| Laurent, R | 2 |
| Mahajan, A | 1 |
| Sharma, H | 1 |
| Bhagat, A | 1 |
| Tandon, VR | 1 |
| Sharma, R | 1 |
| Sharma, S | 1 |
| Phanuphak, N | 1 |
| Apornpong, T | 1 |
| Teeratakulpisarn, S | 1 |
| Chaithongwongwatthana, S | 1 |
| Taweepolcharoen, C | 1 |
| Mangclaviraj, S | 1 |
| Limpongsanurak, S | 1 |
| Jadwattanakul, T | 1 |
| Eiamapichart, P | 1 |
| Luesomboon, W | 1 |
| Apisarnthanarak, A | 1 |
| Kamudhamas, A | 1 |
| Tangsathapornpong, A | 1 |
| Vitavasiri, C | 1 |
| Singhakowinta, N | 1 |
| Attakornwattana, V | 1 |
| Kriengsinyot, R | 1 |
| Methajittiphun, P | 1 |
| Chunloy, K | 1 |
| Preetiyathorn, W | 1 |
| Aumchantr, T | 1 |
| Toro, P | 1 |
| Abrams, EJ | 1 |
| El-Sadr, W | 1 |
| Phanuphak, P | 1 |
| Kra, O | 1 |
| Bamba, V | 1 |
| Ehui, E | 1 |
| Tanon, A | 1 |
| Kassi, NA | 1 |
| Nzunetu, G | 1 |
| Bissagnene, E | 1 |
| Kadio, A | 1 |
| Mehta, U | 1 |
| Vitezica, ZG | 1 |
| Milpied, B | 1 |
| Lonjou, C | 1 |
| Borot, N | 1 |
| Ledger, TN | 1 |
| Lefebvre, A | 1 |
| Hovnanian, A | 1 |
| Kondo, W | 1 |
| Carraro, EA | 1 |
| Prandel, E | 1 |
| Dias, JM | 1 |
| Perini, J | 1 |
| Macedo, RL | 1 |
| Cornelsen, TC | 1 |
| Sbalquiero, R | 1 |
| Sasaki, Md | 1 |
| Ho, TT | 1 |
| Wong, KH | 1 |
| Chan, KC | 1 |
| Lee, SS | 1 |
| Bourezane, Y | 1 |
| Salard, D | 1 |
| Hoen, B | 1 |
| Vandel, S | 1 |
| Drobacheff, C | 1 |
| Rey, D | 1 |
| Partisani, M | 1 |
| Krantz, V | 1 |
| Kempf, G | 1 |
| Nicolle, M | 1 |
| de Mautort, E | 1 |
| Priester, M | 1 |
| Bernard-Henry, C | 1 |
| Lang, JM | 1 |
| Soriano, V | 2 |
| Dona, C | 1 |
| Barreiro, P | 2 |
| González-Lahoz, J | 2 |
| Johnson, S | 1 |
| Baraboutis, JG | 1 |
| Bersoff-Matcha, SJ | 1 |
| Miller, WC | 1 |
| Aberg, JA | 1 |
| van Der Horst, C | 1 |
| Hamrick, HJ | 1 |
| Powderly, WG | 1 |
| Mundy, LM | 1 |
| Palacios Muñoz, R | 1 |
| Santos González, J | 1 |
| Bosch García, R | 1 |
| Márquez Solero, M | 1 |
| Estrada, V | 1 |
| de Villar, N | 1 |
| Serrano-Ríos, M | 1 |
| Lanzafame, M | 1 |
| Rovere, P | 1 |
| De Checchi, G | 1 |
| Trevenzoli, M | 1 |
| Turazzini, M | 1 |
| Parrinello, A | 1 |
| Fagot, JP | 1 |
| Mockenhaupt, M | 1 |
| Bouwes-Bavinck, JN | 1 |
| Naldi, L | 1 |
| Viboud, C | 1 |
| Roujeau, JC | 1 |
| Claudio, GA | 1 |
| Martin, AF | 1 |
| de Dios Perrino, S | 1 |
| Velasco, AA | 1 |
| Messaad, D | 1 |
| Reynes, J | 1 |
| Fabre, J | 1 |
| Bousquet, J | 1 |
| Demoly, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women[NCT00993031] | Phase 3 | 389 participants (Actual) | Interventional | 2009-12-15 | Completed | ||
| A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
antiretroviral hair concentrations (per doubling) (NCT00993031)
Timeframe: delivery
| Intervention | antiretroviral hair concentration(ng/mg) (Mean) |
|---|---|
| Without Protease Inhibitor | 5.7 |
| With Protease Inhibitor | 6.6 |
CD4 cell count recovery efavirenz at delivery (NCT00993031)
Timeframe: Time of randomization to delivery, an average of 20 weeks
| Intervention | CD4 cell count (Median) |
|---|---|
| Without Protease Inhibitor | -7 |
| With Protease Inhibitor | 57 |
Pre-eclampsia Defined by Hypertension > 140/90 on Two Occasions Measured > 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick (NCT00993031)
Timeframe: Time from randomization until delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 0 |
| With Protease Inhibitor | 0 |
(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from delivery until 24 months after delivery or cessation of breastfeeding
| Intervention | treatments (Number) |
|---|---|
| Group A | 21 |
| Group B | 13 |
(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from randomization until 24 months after delivery or cessation of breastfeeding
| Intervention | treatments (Number) |
|---|---|
| With Protease Inhibitor | 17 |
| Without Protease Inhibitor | 17 |
(NCT00993031)
Timeframe: Randomization to one month postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 12 |
| With Protease Inhibitor | 8 |
Virologic suppression was defined as plasma HIV-1 RNA 400 copies/ml or less based on the lower limit of detection of the available test. (NCT00993031)
Timeframe: Time from randomization until delivery, an average of 20 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 166 |
| With Protease Inhibitor | 153 |
HIV tested by DNA PCR (NCT00993031)
Timeframe: Delivery to 48 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 0 |
| With Protease Inhibitor | 2 |
Proportion of women with severe maternal Anemia (hemoglobin < 8g/dl by hemacue or CBC) at any point during the trial in Each Treatment Group (NCT00993031)
Timeframe: Time from randomization until one year follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 11 |
| With Protease Inhibitor | 11 |
Number of participants with positive placental RDT for malaria. Malaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. RDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services. (NCT00993031)
Timeframe: Delivery
| Intervention | participants (Number) |
|---|---|
| With Protease Inhibitor | 6 |
| Without Protease Inhibitor | 7 |
Number of participants with positive placental histopathology slide for malaria (NCT00993031)
Timeframe: Delivery
| Intervention | participants (Number) |
|---|---|
| With Protease Inhibitor | 62 |
| Without Protease Inhibitor | 47 |
Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise >20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(<37wks gestation), neonatal death(death of live-born infant within first 28 days) (NCT00993031)
Timeframe: Time from randomization until 24 months postpartum or cessation of breastfeeding
| Intervention | % of evaluated participants with outcome (Number) |
|---|---|
| With Protease Inhibitor | 33.9 |
| Without Protease Inhibitor | 27.8 |
Number of participants with positive placental blood PCR for malaria (NCT00993031)
Timeframe: Delivery
| Intervention | participants (Number) |
|---|---|
| With Protease Inhibitor | 6 |
| Without Protease Inhibitor | 7 |
Number of participants with positive placental blood smear for malaria (NCT00993031)
Timeframe: Delivery
| Intervention | participants (Number) |
|---|---|
| With Protease Inhibitor | 5 |
| Without Protease Inhibitor | 6 |
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
| Intervention | Number of Adverse Events (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-Threatening | Severe | Moderate | Mild | |
| Nevirapine | 26 | 87 | 375 | 694 | 832 |
| Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
| Intervention | participants (Number) | |
|---|---|---|
| # of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
| Nevirapine | 8 | 700 |
| Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
| Nevirapine | 26 | 678 |
| Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
| Intervention | participants (Number) | |
|---|---|---|
| Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
| Nevirapine | 689 | 629 |
| Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
| Nevirapine | 16 | 664 |
| Placebo | 23 | 663 |
3 reviews available for nevirapine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
[Future direction of pharmacogenomics: identification of genes associated with risk of adverse drug reactions using genome-wide association study].
Topics: Anticonvulsants; Carbamazepine; Dideoxynucleosides; Drug Eruptions; Genetic Predisposition to Diseas | 2014 |
Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Topics: Allopurinol; Anti-HIV Agents; Anticonvulsants; Biomarkers; Carbamazepine; Dideoxynucleosides; Drug E | 2014 |
Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
Topics: Alkynes; Benzoxazines; Chemical and Drug Induced Liver Injury; Cross Reactions; Cyclopropanes; Drug | 2007 |
4 trials available for nevirapine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort S | 2013 |
Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Topics: Adolescent; Area Under Curve; Child; Drug Eruptions; Drug Resistance, Viral; Female; HIV Infections; | 2014 |
Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated.
Topics: Adult; Anemia; Anti-HIV Agents; Blotting, Western; Breast Feeding; Drug Administration Schedule; Dru | 2012 |
Prevention of nevirapine-associated rash.
Topics: Anti-HIV Agents; Drug Eruptions; Humans; Nevirapine | 2001 |
41 other studies available for nevirapine and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash.
Topics: Drug Eruptions; Exanthema; Humans; Lamotrigine; Nevirapine; Oxides; Sertraline; Sulfates; Sulfotrans | 2023 |
Report: A case report on Nevirapine induced exfoliative dermatitis.
Topics: Adult; Anti-HIV Agents; Dermatitis, Exfoliative; Dermatologic Agents; Drug Eruptions; Drug Substitut | 2019 |
Mucocutaneous manifestations of human immunodeficiency virus (HIV) infection in children in relation to the degree of immunosuppression.
Topics: Adolescent; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Eruption | 2019 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazi | 2013 |
Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Drug Therapy, Combination; Female; HIV | 2016 |
Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly A | 2016 |
HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania.
Topics: Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Eruptions; HIV Infections; Huma | 2009 |
Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; CD4 Lymphocyte Cou | 2009 |
A study of the specificity of lymphocytes in nevirapine-induced skin rash.
Topics: Animals; Cell Proliferation; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2009 |
Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical | 2010 |
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
Topics: Anti-HIV Agents; Chromosomes, Human, Pair 6; Drug Eruptions; Genetic Predisposition to Disease; Geno | 2011 |
Six-year retrospective review of drug reaction with eosinophilia and systemic symptoms.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Anti-HIV Agents; Anti-Inflammatory Agents; Anticonvulsa | 2012 |
Hyperhidrosis related to nevirapine therapy.
Topics: Adenine; Aged; Anti-HIV Agents; Drug Eruptions; HIV Seropositivity; Humans; Hyperhidrosis; Lamivudin | 2012 |
Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.
Topics: Adult; Aging, Premature; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Fe | 2012 |
Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2003 |
'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effects.
Topics: Anti-HIV Agents; Dermatitis, Irritant; Diagnosis, Differential; Drug Eruptions; HIV Infections; Huma | 2003 |
Nevirapine-based fixed-dose combination ARVs.
Topics: Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; HIV Infections; Humans; | 2003 |
[Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Eruptions; Exanthema; | 2003 |
Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.
Topics: Administration, Oral; Animals; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Disease Models, Ani | 2003 |
Nevirapine-induced Stevens-Johnson syndrome in a mother and son.
Topics: Adult; Anti-HIV Agents; Child; Drug Eruptions; Female; Humans; Male; Nevirapine; Reverse Transcripta | 2005 |
Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat.
Topics: Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes; Cyclosporine; Disease Models, Animal; Dose-R | 2005 |
[Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Male; | 2005 |
Most common prescribing error in postexposure prophylaxis of HIV/AIDS.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; I | 2007 |
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Topics: Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Infectious Di | 2007 |
[First case of Stevens-Johnson syndrome in a patient treated by Triomune in Abidjan, Côte d'lvoire].
Topics: Anti-HIV Agents; Cote d'Ivoire; Drug Eruptions; Humans; Male; Middle Aged; Nevirapine; Stevens-Johns | 2007 |
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infe | 2008 |
Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Eruptions | 2007 |
High incidence of nevirapine-associated rash in HIV-infected Chinese.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; China; Didanosine; Drug Eruptions; Drug Therapy, Combination; | 1998 |
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Eosinophil | 1998 |
Prednisolone does not prevent the occurrence of nevirapine-induced rashes.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Drug Eruptions; HIV Infections; Humans; Nevirapine; Predn | 1999 |
Europe warned of side effects.
Topics: Chemical and Drug Induced Liver Injury; Drug Eruptions; Europe; HIV Infections; Humans; Liver Failur | 2000 |
Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Exanthema; HIV Infections; Hu | 2000 |
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; I | 2000 |
Sex differences in nevirapine rash.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Eruptions; Exanthema; Female; HIV Infections; Humans; M | 2001 |
[Exanthema in a patient infected with the human immunodeficiency virus after starting antiretroviral treatment].
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Eruptions; HIV Infections; Humans; Male; Nevirapine; Revers | 2000 |
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; HIV Infectio | 2001 |
[Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients].
Topics: Adult; Drug Eruptions; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pneumococcal Vaccines; | 2001 |
Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Eosinophilia; Exanthema; HIV Infectio | 2001 |
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Female; HIV Infections; Humans; Male; | 2001 |
DRESS syndrome associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Monitoring; Eosinophilia; Fever; Humans; Liver Function | 2001 |
Long-term safety and efficacy of nevirapine tolerance induction.
Topics: Adult; Aged; Drug Eruptions; Drug Hypersensitivity; Humans; Immune Tolerance; Male; Middle Aged; Nev | 2002 |